New breakthrough: Italian scientists pioneer a new paradigm for in - vivo gene therapy of hematopoietic stem cells.
Release time:
2025-07-21
In recent years, significant progress has been made in gene therapy for genetic diseases. In particular, the ex - vivo gene therapy strategy based on lentiviral vectors has been successfully applied to diseases such as severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA - SCID). However, existing therapies still face challenges such as high toxic side effects of chemotherapy pre - treatment, complex operations, and high costs, and have limited efficacy for diseases involving multiple tissues.
Recently, the teams led by Luigi Naldini and Michela Milani from the San Raffaele Scientific Institute in Italy published a groundbreaking study in Nature. They proposed an innovative in - vivo gene therapy strategy. By leveraging the biological characteristic of neonatal hematopoietic stem cells migrating from the liver to the bone marrow and combining it with an anti - phagocytic lentiviral vector (CD47high - LV), they successfully achieved efficient and low - toxicity gene modification, opening up a new path for the treatment of genetic blood diseases.
The research team first revealed the dynamic distribution pattern of neonatal hematopoietic stem cells: the number of hematopoietic stem cells in the peripheral blood of newborn mice is more than 10 times that of adult mice, and this numerical advantage persists within 2 weeks after birth. In addition, they precisely mapped the spatio - temporal dynamics of the migration of these cells from fetal hematopoietic organs to the bone marrow. Based on this, the team developed the CD47high lentiviral vector system. The high - expression CD47 molecule (a "don't eat me" signal) on its surface enables it to effectively evade the clearance of the immune system, and they designed multiple tissue - specific promoters to meet the needs of different diseases.
In three genetic disease models, this strategy showed significant efficacy:
In the ADA - SCID model: The survival rate of the treatment group reached 71%, significantly better than that of the control group, and the liver detoxification function synergistically enhanced the treatment effect.
In the Fanconi anemia model: Gene - corrected cells showed a selective advantage under the pressure of bone marrow failure, and the vector copy number increased from 0.1 to 1.0, almost completely reconstructing the hematopoietic system.
In the osteopetrosis model: Although the efficacy was limited, it confirmed the feasibility of the technology itself, and the rapid progression of the disease was the main limiting factor.
Notably, the number of hematopoietic stem cells in the peripheral blood of human neonates is also significantly higher than that of adults, providing direct evidence for clinical translation.
This study not only breaks through the bottleneck of ex - vivo gene therapy but also avoids the risks of chemotherapy pre - treatment and significantly reduces the treatment cost. This innovative paradigm provides a new solution for early - onset genetic diseases and marks a leap from "ex - vivo manipulation" to "in - vivo precise repair" in gene therapy. In the future, with the advancement of clinical translation, it is expected to bring hope of cure to more patients with genetic diseases.
Previous article
Previous article
Latest developments
Recently, the "Novel Technology for Ultra-Low Temperature Cryopreservation, Activation, and Transplantation of Human Ovarian Tissue," developed through a collaborative effort between Shandong Yinfeng Life Science Research Institute and Beijing University of Chinese Medicine Shenzhen Hospital, has been awarded the 2025 Shandong Refrigeration and Air Conditioning Science and Technology Award. This groundbreaking technology pioneers a new pathway for female fertility preservation, marking a significant leap in China’s interdisciplinary advancements in reproductive medicine and cryobiology.
On May 19, a delegation from the Chinese Training Workshop for Government Officials of Developing Countries visited the exhibition hall of Yinfeng Biological Group's Cryomedicine Research Center. Government officials from multiple countries gained in-depth insights into Yinfeng’s innovative achievements in cryobiomedicine, cell storage, genetic technology, and other fields. They engaged in discussions with the delegation on technology transfer and international cooperation, contributing to the building of a global community with a shared future for humanity.
On the morning of May 17, 2025, an immersive exploration into life sciences and cryomedicine concluded successfully at Jinan Yinfeng Biological Science Park. Hosted by the Shandong Yinfeng Life Science Research Institute, this event offered members a firsthand look into the research base through activities such as ultra-low temperature cryotherapy experiences, brainwave signal acquisition system trials, and expert panel discussions. Participants witnessed the infinite possibilities that cryogenic technology and life sciences hold for humanity.
The international academic platform ScholarGPS recently announced its global lists of Highly Ranked Scholars - Lifetime and Highly Ranked Scholars - Prior 5 Years, recognizing the top 0.05% of scholars across various disciplines. Among the selected Chinese scholars are national-level talents, leading figures in specialized fields, and seasoned academics dedicated to long-term research.
In January 2025, members of the Yinfeng cryomedicine team actively participated in the "Sino-French Aerial Emergency Medical Rescue Training" and obtained certification. This signifies a further enhancement of the team's professional capabilities in the field of international emergency medical rescue.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155507
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
